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ttp://dx.doi.org/10.1016/j.ajpath.2015.01.018Obesity poses an increased risk of developing metabolic syndrome and closely associated nonalcoholic
fatty liver disease, including liver cancer. Satiety hormone leptin-deﬁcient (ob/ob) mice, considered
paradigmatic of nutritional obesity, develop hepatic steatosis but are less prone to developing liver
tumors. Sustained activation of peroxisome proliferatoreactivated receptor a (PPARa) in ob/ob mouse
liver increases fatty acid oxidation (FAO), which contributes to attenuation of obesity but enhances
liver cancer risk. To further evaluate the role of PPARa-regulated hepatic FAO and energy burning in the
progression of fatty liver disease, we generated PPARa-deﬁcient ob/ob (PPARaDob/ob) mice. These
mice become strikingly more obese compared to ob/ob littermates, with increased white and brown
adipose tissue content and severe hepatic steatosis. Hepatic steatosis becomes more severe in fasted
PPARaDob/ob mice as they fail to up-regulate FAO systems. PPARaDob/ob mice also do not respond to
peroxisome proliferative and mitogenic effects of PPARa agonist Wy-14,643. Although PPARaDob/ob
mice are severely obese, there was no signiﬁcant increase in liver tumor incidence, even when main-
tained on a diet containing Wy-14,643. We conclude that sustained PPARa activationerelated increase
in FAO in fatty livers of obese ob/ob mice increases liver cancer risk, whereas deletion of PPARa in
ob/ob mice aggravates obesity and hepatic steatosis. However, it does not lead to liver tumor devel-
opment because of reduction in FAO and energy burning. (Am J Pathol 2015, 185: 1396e1408; http://
dx.doi.org/10.1016/j.ajpath.2015.01.018)Supported by NIH grants DK083163 and DK097240 (J.K.R.),
R21A1094296 (B.T.), DK60015 and DK58614 (B.P.), and DK60635
(Y.S.K.) and the China Scholarship Council grant CSC 2011630169 (Q.G.).
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Disclosures: None declared.Obesity, a disorder involving chronic energy imbalance
resulting from excess caloric intake and reduced energy
expenditure, was estimated to affect 671 million adults globally
in 2013.1,2 Furthermore, in 2013, another 1.4 billion adults were
considered to become overweight.1 Overall, the prevalence of
overweight with a body mass index of25 to<30 kg/m2, and
obesity with a body mass index of 30 kg/m2, in adults aged
>18 years has increased substantially during the past three
decades (1980 to 2013).1 In the United States, obesity rates are
among the highest in the world, with approximately 70% of
Americans being overweight or obese.2 Because of the estab-
lished health risks, such as insulin resistance, metabolic syn-
drome, type 2 diabetes mellitus, atherogenic dyslipidemia, and
nonalcoholic fatty liver disease, obesity has become a majorstigative Pathology.
.global health challenge.1 Nonalcoholic fatty liver disease
of obesity begins with simple hepatic steatosis that pro-
gresses to nonalcoholic steatohepatitis with inﬂammation,
hepatocellular injury, liver cell proliferation, and ﬁbrous
scarring, culminating in end-stage liver disease of cirrhosis
and liver cancer.3e6 On the basis of the burgeoning
pandemic of nutritional obesity, it is projected that 25
million Americans will likely develop nonalcoholic
PPARa-Deﬁcient ob/ob Obese Micesteatohepatitis by 2025, with approximately 20% pro-
gressing to cirrhosis of liver, with an added risk of devel-
oping hepatocellular carcinoma.7
In obesity, the unburnt energy is conserved in the form
of fat (triacylglycerol), ﬁrst in adipocytes considered
limitless reservoirs of fat and subsequently in liver
considered as a surrogate reservoir for fat, when adipose
fat stores are nearly saturated.8e10 Liver is a central player
in whole body energy homoeostasis by its ability to
metabolize glucose and fatty acids, with surplus glucose
converted to fat for storage.11 Hepatic steatosis occurs
under a variety of conditions, especially when the rate of
hepatic fatty acid uptake from plasma and de novo fatty
acid synthesis from glucose is greater than the rate of fatty
acid oxidation (FAO).12 Excess storage of lipid in liver
without inﬂammation (bland hepatic steatosis) by itself is
insufﬁcient to increase liver cancer risk in obesity, as noted
in ob/ob mice deﬁcient in satiety hormone leptin.13
Enhancement of FAO in these ob/ob fatty livers by sus-
tained activation of peroxisome proliferatoreactivated
receptor (PPAR)-a leads to nonalcoholic steatohepatitis
and enhanced endoplasmic reticulum stress, contributing
to a high incidence of liver tumors.14 PPARa, because of
its unique ability to regulate FAO in liver, plays a signif-
icant role in the pathogenesis of hepatic steatosis and in
the development of hepatocellular carcinomas in rats
and mice.15,16 PPARa-null mice (PPARa/) are unable
to up-regulate the expression of FAO-associated genes
and, as a consequence, they develop hepatic steatosis
but fail to develop liver tumors in response to chronic
exposure to peroxisome proliferators.17e19 Accordingly,
these observations support the concept that PPARa-
regulated increases in FAO contribute to the develop-
ment of liver tumors in nonalcoholic fatty liver
disease.3,4
Herein, we examined the impact of PPARa deﬁciency
on the obesity and fatty liver of leptin-deﬁcient mice.
PPARa-deﬁcient mice were crossed with heterozygous
leptin-deﬁcient OB/ob mice to generate PPARa-deﬁcient
ob/ob (PPARaDob/ob) mice. Deletion of PPARa in these
obese ob/ob mice aggravates obesity because of increases
in white and brown fat content and fasting-induced hepatic
steatosis because of the failure to increase fatty acid
oxidation capacity in the absence of PPARa. Despite se-
vere hepatic steatosis, PPARaDob/ob mice do not develop
liver tumors, because they fail to increase FAO and energy
burning necessary for the induction of oxidative and
endoplasmic reticulum stresses that play a role in liver
tumor development.14,15
Materials and Methods
Animals
Acox1-deﬁcient (Acox1/) mice20 and PPARa-deﬁcient
(PPARa/) mice21 were maintained on a C57BL/6JThe American Journal of Pathology - ajp.amjpathol.orgbackground as breeding colonies. The generation of
Acox1-deﬁcient ob/ob (Acox1Dob/ob) mice was described
previously.22 To generate PPARa-deﬁcient ob/ob mice
(PPARaDob/ob), heterozygous leptin-deﬁcient OB/ob
mice (The Jackson Laboratory, Bar Harbor, ME) were crossed
with PPARa/ mice to obtain heterozygous PPARaþ//OB/
ob mice, which were further bred to produce PPARa-deﬁcient
ob/ob double-mutant mice designated PPARaDob/ob mice
(Supplemental Figure S1).
The mice were genotyped by PCR of genomic DNA iso-
lated from tail tips obtained at the age of 3 weeks. To identify
ob/ob mice, primers used were as follows: 50-TGTCCAA-
GATGGACCAGACTC-30 (forward) and 50-ACTGGTCT-
GAGGCAGGGAGCA-30 (reverse). For PPARa-null mice,
the primers used were as follows: 50-CTTGGGTGGAGA-
GGCTATTC-30 (forward) and 50-AGGTGAGATGACAGG-
AGATC-30 (reverse). For genotyping Acox1mice, the primers
used were as follows: 50-TATTCGGCTATGACTGGG-
CACA-30 (forward) and 50-GATGGATACTTTCTCGGCA-
GGA-30 (reverse).22
All mice were maintained in polypropylene cages in a
temperature-controlled (23C) environment using a standard
photoperiod (12 hours light and 12 hours dark cycle) with
lights on at 6 AM. Mice were provided rodent chow (Teklad
7904; Harlan-Teklad, Indianapolis, IN) with or without
added PPARa activator Wy-14,643 (0.05% or 0.125% w/w)
and water ad libitum.
For food intake measurement, three mice were housed
individually, and the daily caloric intake was determined
over a 7-day period and normalized against the initial body
weight (kcal/g body weight per day). These measurements
were repeated three times using different batches of mice.
To assess hepatocyte proliferation, mice were adminis-
tered 0.5 mg/mL bromodeoxyuridine (BrdUrd) in drinking
water and sacriﬁced at the end of 3 days. All procedures of
animal handling were approved by the Institutional Animal
Care and Use Committees of Northwestern University
(Chicago, IL; protocol number 2013-3198).
Glucose Tolerance and Insulin Tolerance Tests
Wild-type (WT), PPARa/, ob/ob, and PPARaDob/ob
mice (aged 3 months; ﬁve mice in each group) were used
for determining glucose tolerance and insulin tolerance
essentially as described previously.22 Brieﬂy, glucose (1.5
mg/g body weight in phosphate-buffered saline) was
administered i.p. to mice that were maintained without
food for 6 hours.22,23 Blood obtained from tail vein at 0, 30,
60, and 120 minutes after administering glucose was used
for measuring glucose using a glucose meter (One Touch;
LifeScan, Milpitas, CA). For testing insulin tolerance,
mice deprived of food for 4 hours were given insulin (0.75
mU/g body weight in phosphate-buffered saline; Sigma,
St. Louis, MO) by an i.p. injection. Blood glucose levels
were determined at 0, 15, 30, and 60 minutes after insulin
injection.1397
Table 1 Primers for Genotyping, Quantitative PCR, and Northern Blot Analysis
Primer name Forward primer Reverse primer
PPARa ko geno 50-CTTGGGTGGAGAGGCTATTC-30 50-AGGTGAGATGACAGGAGATC-30
PPARa wt geno 50-CCATCCAGATGACACCTTCC-30 50-TCTCTTGCAACAGTGGGTGC-30
ob/ob geno 50-TGTCCAAGATGGACCAGACTC-30 50-ACTGGTCTGAGGCAGGGAGCA-30
Neo geno 50-TATTCGGCTATGACTGGGCACA-30 50-GATGGATACTTTCTCGGCAGGA-30
ACOX1 geno 50-CCGCAAGCCATCCGACATTC-30 50-ATTCAGTGGGTCAGGCGACTGC-30
PPARa 50-GGGCTCCGAGGGCTCTGTCA-30 50-TGCAGCTCCGATCACACTTGTCG-30
Acox1 50-GCCAAGGCGACCTGAGTGAGC-30 50-ACCGCAAGCCATCCGACATTC-30
L-PBE/Ehhadh 50-GGTCGTTGGAGTTCCTGTTGCT-30 50-TGGGCAAGCTTGGGACTGGC-30
SCAD 50-GCTGAGTGGTGCAGGCTTG-30 50-CCATTGGTGAAAGGGGTGATC-30
MCAD 50-GGATGACGGAGCCAATG-30 50-GGGTGTCGGCTTCCACAATG-30
LCAD 50-GACGGCGGGCAAGTGTATC-30 50-GCAGGCGATCGAGCTTCAC-30
Cyp4a1 50-AGGATGAGGGAGAGCTGGAAAAGAT-30 50-GACTCCACTGGCTGTGGTGTCATG-30
Cyp4a3 50-GCAGAAGGCCAGGAAGAGACAC-30 50-CCAGAGCATAGAAAATCCAGGAAATT-30
PPARg 50-CCACAGTTGATTTCTCCAGCATTTC-30 50-CAGGTTCTACTTTGATCGCACTTTG-30
PGC1a 50-CTCCATGCCTGACGGCACCC-30 50-GCAGGGACGTCTTTGTGGCT-30
Sirt1 50-GGATGATATGACGCTGTGGC-30 50-AGAGACGGCTGGAACTGTCC-30
FGF21 50-TGGGGGTCTACCAAGCATAC-30 50-AAGGCTCTACCATGCTCAGG-30
PEPCK 50-TGAACTGACAGACTCGCCCT-30 50-GTCTTCCCACAGGCACTAGG-30
PTL 50-TCTCCAGGACGTGAGGCTAAA-30 50-CGCTCAGAAATTGGGCGATG-30
Nrf2 50-GATGGACTTGGAGTTGCCAC-30 50-GTTTGGGAATGTGGGCAACC-30
P8 50-CTCCCTCTCCAGAACCTCACT-30 50-ACCAAGAGAGAAGCTGCTGC-30
18S 50-AAACGGCTACCACATCCAAG-30 50-CCTCCAATGGATCCTCGTTA-30
ACOX, acyl-Coenzyme A oxidase; FGF, ﬁbroblast growth factor; LCAD, long-chain acyl-CoA dehydrogenase; L-PBE, L-3-hydroxyacyl-CoA dehydrogenase; MCAD,
medium-chain acyl-CoA dehydrogenase; PEPCK, phosphoenolpyruvate carboxykinase; PGC, peroxisome proliferator-activated receptor gamma, coactivator;
PPAR, peroxisome proliferatoreactivated receptor; PTL, 3-ketoacyl-CoA thiolase; SCAD, short-chain acyl-CoA dehydrogenase.
Gao et alBiochemical Assays
Liver samples were homogenized for extraction of lipid using
chloroform/methanol method. Triacylglycerol (Thermo Elec-
tron, Louisville, CO) and total cholesterol (Wako Diagnostics,
Richmond, VA) levels were determined as described else-
where.24 Blood obtained from retro-orbital veins was used for
triglyceride and total cholesterol determinations.25,26
Histology and Immunohistochemistry
For histological analysis, liver slices were ﬁxed in 4% para-
formaldehyde and processed for embedding in parafﬁn.
Parafﬁn sections (4 mm thick) were cut and stained with
hematoxylin and eosin. For visualization of cellular fat,
frozen sections of liver (approximately 5 mm thick) were
stained with 0.5% Oil Red O solution for 30 minutes in a
60C oven and then in 85% propylene glycol solution for 5
minutes. After rinsing with distilled water, sections were
stained with Gill’s hematoxylin for 2 seconds, washed, and
mounted with aqueous mounting medium.22,27 Parafﬁn sec-
tions were also used for Sirius Red staining.28 Liver sections
were also processed for the localization of catalase, L-PBE
(enoyl-Coenzyme A, hydratase; EHHADH), and BrdUrd, as
described elsewhere.20,29 BrdUrd nuclear labeling indices
were obtained by analyzing immunohistochemically stained
liver sections.30 All images were acquired by a light microscope
adapted to a high-resolution camera (AxioCam; Carl Zeiss,
Oberkochen, Germany) and analyzed by the computer using
AxioVisionRel software version 4.8 (Carl Zeiss).1398Immunoblotting
For immunoblotting, 40 mg liver protein samples were sub-
jected to 4% to 20% SDS-PAGE, transferred to nitrocellulose
membrane, and blotted using antibodies against PPARa, L-3-
hydroxyacyl-CoA dehydrogenase (L-PBE), acyl-CoA oxidase
1, palmitoyl (Acox1), short-chain acyl-CoA dehydrogenase
(SCAD), medium-chain acyl-CoA dehydrogenase (MCAD),
long-chain acyl-CoA dehydrogenase, peroxisomal 3-ketoacyl-
CoA thiolase A (PTL), D-3-hydroxyacyl-CoA dehydratase
(D-PBE), and catalase, as described elsewhere.29,31 b-Actin
(antibody sc-47778; Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) was used as loading control.
Northern Blotting and Real-Time PCR
Total RNA was isolated from mouse liver with TRIzol reagent
(Invitrogen, Life Technologies, Carlsbad, CA). For Northern
blotting, RNA was glyoxylated, separated on a 1% agarose
gel, transferred to a nylon membrane, hybridized at 65C in
Rapid-hyb buffer (GE Healthcare, Piscataway, NJ), and pro-
bed with a-32Pelabeled cDNA.29,32 RNAs (28S and 18S)
were set as the loading controls. For real-time PCR, total RNA
isolated from liver was reverse transcribed to make cDNA
using the Superscript III ﬁrst-strand synthesis system for RT-
PCR (Invitrogen Life Technologies). The primers used for
the real-time PCR are listed in Table 1. Quantitative expres-
sion of genes was checked using SYBR Green (Applied
Biosystems, Foster City, CA) in triplicate and normalized with
18S ribosomal RNA. PCR was composed of 1 mL (100 rmol)ajp.amjpathol.org - The American Journal of Pathology
Figure 1 PPARaDob/ob mice become super obese. A: Physical appearance of chow-fed 16-month-old wild-type (WT), PPARa/, ob/ob, and PPARaDob/ob
mice. Acox1Dob/ob and Acox1/ mice that manifest PPARa activation by endogenous ligands are included for comparison. B: Age-related body weight
changes of WT, PPARa/, ob/ob, and PPARaDob/ob mice, aged 4 to 52 weeks. C: For food consumption estimation, three mice in each group were housed in
separate cages, and daily food intake (kcal) per body weight was determined by measuring 7-day consumption. *P < 0.05, **P < 0.01 versus WT; yP < 0.05,
yyP < 0.01 versus PPARa/; zP < 0.05 versus ob/ob.
PPARa-Deﬁcient ob/ob Obese Miceof forward and reverse primers and 10 mL of 2 SYBR Green
PCRMaster Mix and performed by using an ABI 7300 system
(Applied Biosystems). The generation of speciﬁc PCR prod-
ucts was conﬁrmed by melting curve analysis, and the relative
gene expression changes were measured using the compara-
tive Ct method: X Z 2eDDCt:
Statistical Analysis
Data were analyzed by one-way analysis of variance using
SPSS software version 11.5 (SPSS, Chicago, IL). P < 0.05
was considered signiﬁcant.
Results
Obese ob/ob Mice Lacking PPARa Become Super Obese
Because of subfertility of homozygous ob/ob mice, hetero-
zygousOB/obmice were mated with PPARa/ (PPARa/
with OB/OB) mice to generate double-heterozygousThe American Journal of Pathology - ajp.amjpathol.orgPPARaþ/ OB/ob mice. These mice, when intercrossed,
yielded PPARaDob/ob mice used in these studies
(Supplemental Figure S1A). PCR ampliﬁcation of genomic
DNA from double-nullizygous PPARaDob/ob mice yiel-
ded 55- and 100-bp bands for ob/ob and a 280-bp band for
PPARa/ (Supplemental Figure S1B). DNA from WT
mice showed one 143-bp band and one 155-bp band for
PPARaþ/þ andOB/OB, separately (Supplemental Figure S1B).
PPARa mediates the pleiotropic responses induced in liver
by peroxisome proliferators.16,21,33 These include hepato-
megaly, peroxisome proliferation, and transcriptional activa-
tion of genes encoding peroxisomal, mitochondrial, and
microsomal FAO enzymes.16,34 Previous studies demon-
strated that Acox1 deletion disrupts metabolism in WT mice,
and ob/obmice are smaller and leaner than bothWT and ob/ob
mice.20,22 In the absence of Acox1, the unmetabolized sub-
strates of this enzyme serve as endogenous PPARa activa-
tors.16,32 Sustained activation of PPARa by its endogenous
ligands in Acox1Dob/ob mice (Figure 1A) increases hepatic
fatty acid oxidation and attenuates obesity.22 In contrast,1399
Figure 2 Fat accumulation in the inguinal white adipose tissue (WAT)
and scapular brown adipose tissue (BAT). A: Histological features of WAT
and BAT of 3-month-old wild-type (WT), PPARa/, ob/ob, and PPAR-
aDob/ob mice. B and C: Fat:body weight ratios.
Gao et aldeletion of PPARa in the ob/ob background (PPARaDob/ob)
resulted in a further increase in somatic growth compared to
their ob/ob littermates (Figure 1, A and B). Fromweaning until
approximately the age of 6 weeks, somatic growth of PPAR-
aDob/ob mice did not signiﬁcantly differ from ob/ob mice.
However, by the age of 24 weeks, PPARaDob/obmice gained
more weight than ob/ob mice and were distinctly more obese
(super obese) than ob/obmice (Figure 1, A and B). There was
no signiﬁcant difference in food intake of WT and PPARa/
mice, but food consumption in ob/ob mice was slightly more
than that of PPARaDob/ob mice. These ﬁndings suggest that
increased obesity observed in PPARaDob/ob mice is not due
to increased food intake but related to decreased energy
expenditure associated with PPARa deletion (Figure 1C).
Examination of 3- and 6-month-old PPARaDob/ob and
ob/ob mice revealed a consistent increase in the amount of
inguinal white adipose tissue (WAT) and interscapular brown
adipose tissue (BAT) in both ob/ob and PPARaDob/ob
mice, but the increase was more prominent in double nulls
(Supplemental Table S1). At 6 months of age, the WAT inWT
mice was 0.56 g compared to 4.22 g in ob/obmice and 5.87 g in
PPARaDob/ob mice. In 6-month-old WT mouse, BAT was
0.14 g compared to 1.19 g in ob/ob mice and 1.37 g in
PPARaDob/ob mice (Supplemental Table S1).
Histological examination of WAT revealed no signiﬁcant
difference in the adipocyte size of PPARaDob/ob mice when1400compared with ob/ob mice (Figure 2A). In both ob/ob and
PPARaDob/ob mice, BAT whitened with several large lipid
droplets, and this change was considerably greater in PPAR-
aDob/ob mice (Figure 2A). At 6 months of age, the WAT and
BAT body weight ratios were increased in PPARaDob/obmice
(Figure 2, B and C). Leptin-deﬁcient ob/ob mice exhibit hy-
perphagia and obesity, along with hyperglycemia and hyper-
insulinemia.35 PPARa knockout mice appear normal, but the
circulating glucose is lower, with increased serum insulin
level.23 PPARaDob/ob mice exhibited higher serum glucose
level and lower insulin level comparedwithWT and ob/obmice
(Supplemental Figure S2, A and B). PPARa deﬁciency
improved insulin and glucose tolerance in obese mice.
PPARa Deﬁciency Aggravates Hepatic Steatosis in
ob/ob Mice
PPARa deﬁciency in ob/ob mice results in an increased
accumulation of fat in liver as compared to that in ob/ob livers
(Figure 3). At 3 and 6 months of age, liver/body weight ratios
were higher in PPARaDob/ob mice than in ob/ob mice
(Supplemental Table S1), and on histological examination,
including Oil Red O staining for fat, these livers revealed
prominent macrovesicular steatosis (Figure 3). Overall, in
PPARaDob/ob mouse hepatocytes, fat droplets appeared
much larger at 3 and 6 months of age (Figure 3). Hepatic
triglyceride and cholesterol content was higher in 6-month-
old PPARaDob/obmice as compared toWT, PPARa/, and
ob/ob mice (Supplemental Figure S2, C and D).
Aging Attenuates Hepatic Steatosis in PPARaDob/ob
Mice and Induces Hepatic Oval Cell Proliferation
There was a reduction in hepatic steatosis in both ob/ob and
PPARaDob/ob mice aged 16 months or older (Figure 3). In
PPARaDob/ob mice, liver displayed cellular heterogeneity
with mild pericellular ﬁbrosis and emerging clusters of oval
cells (Figure 3). Severe hepatic steatosis in double-knockout
mice increased hepatocyte apoptosis and hepatocyte regener-
ation independent of PPARa to replace the dead liver cells
(data not shown). Oval cells in PPARaDob/ob mouse liver,
occurring either singly or in clusters, stained positively on
immunohistochemical analysis (Supplemental Figure S3A)
for oval cell markers A6, CD45, CK19, and epithelial cell
adhesion molecule.36,37 Quantitative PCR analysis revealed
robust expression of these genes in aged PPARaDob/obmouse
livers, but albumin levels were low and a-fetoprotein was high
(Supplemental Figure S3B).
Severe Fatty Liver in Fasted PPARaDob/ob Mice
During periods of starvation, triglycerides stored in adipose
tissue are hydrolyzed to free fatty acids and mobilized into
plasma to reach liver. In liver, they are oxidized by the mito-
chondrial b-oxidation system and, to a lesser extent, by the
peroxisomal b-oxidation, as well as by CYP4A-catalyzedajp.amjpathol.org - The American Journal of Pathology
Figure 3 PPARaDob/ob mice exhibit severe hepatic steatosis. PPARa deﬁciency aggravates hepatic steatosis in ob/ob mice (see ob/ob versus
PPARaDob/ob). Liver sections of 3-month-old (A and B), 6-month-old (C and D), 16-month-old (E) wild-type (WT), PPARa/, ob/ob, and PPARaDob/ob
mice maintained on a chow diet were stained with hematoxylin and eosin (A, C, and E) and Oil Red O (B and D). F: Sirius Red staining of liver sections of 16-
month-old mice. PPARaDob/ob mice reveal a discernible increase in Sirius Redepositive ﬁbrous septa.
PPARa-Deﬁcient ob/ob Obese Micemicrosomal u-oxidation pathways to generate ketone bodies
that include acetoacetate, 3-hydroxybutyrate (alias b-hydrox-
ybutyrate), and acetone.38 These serve as fuel for nonhepatic
peripheral tissues.38 Because PPARa is vital for the tran-
scriptional regulation of fatty acidemetabolizing enzymes in
liver, the deﬁciency of this transcription factor in starvation
leads to hepatic steatosis.39,40 To ascertain the combined ef-
fects of decreased energy burning due to PPARa deﬁciency
and increased food intake due to lack of leptin during starva-
tion, WT, PPARa/, ob/ob, and PPARaDob/ob mice were
fasted for 24, 48, and 72 hours (Figure 4). After 24 hours
starvation, PPARa/ and PPARaDob/ob mouse livers were
paler and larger, suggestive of fatty change when compared to
fasted WT and ob/ob livers (Figure 4A). The difference inThe American Journal of Pathology - ajp.amjpathol.orgpallor was exaggerated with prolonged fasting (Figure 4A). In
contrast, pallor in ob/ob mouse liver was reduced after star-
vation (Figure 4A).
Hematoxylin and eosin and Oil O Red staining results
conﬁrmed severe hepatic steatosis in PPARa/ and
PPARaDob/ob mice after starvation (Figure 4, B and C).
Hepatic steatosis observed in fed ob/ob mice diminished due
to fasting-induced activation of PPARa regulated fatty acid
oxidation in liver (Figure 4, B and C). No fat droplets are
seen in WT and ob/ob mouse livers starved for 48 and 72
hours (Figure 4, B and C). The glycogen content in livers
of all animals was reduced after fasting (data not shown).
Serum glucose levels of PPARa/ and PPARaDob/ob mice
were reduced to approximately 47% and 30.3% of basal level1401
Figure 4 PPARa deﬁciency increases hepatic steatosis after starvation and reduces plasma glucose signiﬁcantly. A: Representative gross images of livers of
fed and 24-, 48-, and 72-hour fasted wild-type (WT), PPARa/, ob/ob, and PPARaDob/ob mice. B: Hematoxylin and eosin staining of livers of WT, PPARa/,
ob/ob, and PPARaDob/ob mice fed and fasted for 24, 48, and 72 hours. C: Oil Red Oestained liver sections conﬁrm fat accumulation in PPARa/ and
PPARaDob/ob mice, but attenuation of steatosis in ob/ob mice. D: Plasma glucose levels are higher in ob/ob mice compared to other genotypes. *P < 0.05
versus WT, yP < 0.05 versus PPARa/, and zP < 0.05 versus ob/ob.
Gao et alafter 24 hours starvation, respectively, and no further reduc-
tion was noted with prolonged fasting (Figure 4D).
Northern andWestern blot analyses of liver samples obtained
from WT and ob/ob mice starved for 24 hours revealed in-
creases in the mRNA and/or protein levels of Acox1, L-PBE
(EHHADH), MCAD, long-chain acyl-CoA dehydrogenase,
CYP4A1, CYP4A3, and ﬁbroblast growth factor 21 after 24
hours of fasting (Figure 5, A and B). Quantitative PCR data
revealed increases in PPARa level in livers of fasted WT and
ob/obmice (Figure 5). Increased mRNA content of peroxisome
proliferator-activated receptor gamma, coactivator 1 alpha
(PGC1a) was noted in 24- and 48-hour fasted WT livers. Sirt1
level increased in PPARaDob/ob mouse liver at 48 and 72
hours starvation, and phosphoenolpyruvate carboxykinase
level increased in normal and ob/ob mouse livers at 48
hours of fasting (Figure 5C).
PPARa Ligand Does Not Induce Liver Tumors in
PPARaDob/ob Mice
Previous studies have shown that increased FAO and
energy combustion in liver leads to liver tumor1402development.15 Sustained activation of PPARa in ob/ob
mice attenuates obesity by increasing hepatic FAO but
increases the risk for liver tumor development, in part,
related to excess energy combustion.22 To study the in-
ﬂuence of PPARa deﬁciency in PPARaDob/ob mice, we
ﬁrst evaluated the effects of short-term administration of
Wy-14643, a PPARa ligand (Figure 6). We found, as ex-
pected, that PPARaDob/ob mice fail to respond to PPARa
ligand Wy-14,643 administered in powdered chow at
0.125% for 4 days (Figures 6 and 7).
Induction of PPARa-regulated genes in liver, in partic-
ular those involved in FAO, was not observed in PPAR-
aDob/ob mice (Figure 6). We also evaluated BrdUrd
incorporation in hepatocyte nuclei and expression level of
L-PBE, the second enzyme of the peroxisomal b-oxidation,
by immunohistochemical analyses (Figure 7, A and B).
The liver/body weight ratio increased in WT and ob/ob
mice fed Wy-14,643 for 4 days, but no increase was
evident in PPARaDob/ob mice (Figure 7C). BrdUrd la-
beling indices in liver increased variably in WT and ob/ob
mice given Wy-14,643 (Figure 7, A and D). It would
appear that the increased nuclear labeling in these mice isajp.amjpathol.org - The American Journal of Pathology
Figure 5 Constitutive and 24-hour starvation inducible levels of fatty acid oxidation gene expression in livers of wild-type (WT), PPARa/, ob/ob, and
PPARaDob/ob mice. Representative Northern (A) and Western (B) blots to assess the gene expression changes in liver. C: Quantitative PCR data of key enzymes
linked to acute fasting. Acox, acyl-Coenzyme A oxidase; D-PBE, D-3-hydroxyacyl-CoA dehydratase; FGF, ﬁbroblast growth factor; LCAD, long-chain acyl-CoA
dehydrogenase; L-PBE, L-3-hydroxyacyl-CoA dehydrogenase; MCAD, medium-chain acyl-CoA dehydrogenase; PEPCK, phosphoenolpyruvate carboxykinase; PGC,
peroxisome proliferator-activated receptor gamma, coactivator; SCAD, short-chain acyl-CoA dehydrogenase.
PPARa-Deﬁcient ob/ob Obese MicePPARa linked, and the small, but perceptible, increase in
control andWy-14,643etreated PPARaDob/obmice is PPARa
independent.
Sustained activation of PPARa by both synthetic and
endogenous ligands results in the development of hepatocellular
carcinomas in mice.15,22,32 Herein, we examined the role of
chronic exposure to PPARa ligand Wy-14,643 in PPAR-
aDob/obmice (Figure 8). InWT and ob/obmice chronically fed
a Wy-14,643econtaining diet, body weights were lower than
the chow-fed controls, whereas absence of PPARa, in
PPARa/ mice and PPARaDob/ob mice, exerted no sig-
niﬁcant change in body weights (Figure 8, A and B). All
mice that survived were sacriﬁced at 52 weeks of age, and
liver tumor incidence was obtained (Figure 8, C and D).
Although all ob/ob mice survived at 1 year, the survival
probability was reduced during this period in PPARaDob/
obmice. Liver tumors were seen in 9 of 10WT, and 10 of 11
ob/ob, mice fed PPARa ligand, but the incidence of liver
tumors in ob/ob mice maintained on normal chow was low
(3/12). PPARaDob/ob mice fed a normal or Wy-14,643e
containing diet had tumor incidence similar to that ofThe American Journal of Pathology - ajp.amjpathol.orgchow-fed ob/ob mice. No liver tumors were detected
in PPARa/ mice maintained on a control (0/10) or
Wy-14,643econtaining diet (0/10). We included data
obtained from Acox1/ and Acox1Dob/ob mice on a con-
trol diet. Both these groups with sustained PPARa activation
due to endogenous ligands developed a high incidence of liver
tumors. All tumors were well to moderately differentiated
hepatocellular carcinomas.
Discussion
PPARa and Energy Burning
Activation of lipid-sensing nuclear receptor PPARa in liver
promotes the uptake, use, and catabolism of fatty acids by
transcriptional up-regulation of genes involved in these
physiological processes.8,16,33,41 In liver, PPARa plays a
central role in the regulation of energy burning by peroxi-
somal and mitochondrial fatty acid b-oxidation and micro-
somal u-oxidation.8,15 PPARa is activated by a plethora of
synthetic exogenous ligands that include ﬁbrate and other1403
Figure 6 Constitutive and Wy-14,643einducible levels of fatty acid oxidation gene expression in livers of wild-type (WT), PPARa/, ob/ob, and PPARaDob/ob
mice. Representative Northern (A) and Western (B) blots to assess the gene expression changes in liver. C: Quantitative PCR data of key enzymes linked to fatty acid
oxidation. Acox, acyl-Coenzyme A oxidase; D-PBE, D-3-hydroxyacyl-CoA dehydratase; LCAD, long-chain acyl-CoA dehydrogenase; L-PBE, L-3-hydroxyacyl-CoA
dehydrogenase; MCAD, medium-chain acyl-CoA dehydrogenase; PTL, 3-ketoacyl-CoA thiolase; SCAD, short-chain acyl-CoA dehydrogenase.
Gao et alclasses of drugs used in the treatment of hyperlipidemia and
also by industrial plasticizers, insecticides, herbicides, and
certain organic solvents that are collectively referred to as
peroxisome proliferators.15e17Metabolic Pathways that Generate and Degrade
Endogenous PPARa Ligands Exist to Modulate Lipid
Metabolism: Acox1 in the Metabolism of Endogenous
PPARa Activators
The existence of endogenous biological molecules that
activate PPARa in vivo ﬁrst became evident in mice with
the germline deletion of Acox1, the ﬁrst and rate-limiting
enzyme of the peroxisomal fatty acid b-oxidation
pathway.20,32 Acox1 deﬁciency results in the generation of
a lean mouse with a complex hepatic phenotype mani-
festing as steatohepatitis, hepatocellular regeneration with
massive spontaneous proliferation of peroxisomes, and
concomitant perpetually heightened transcriptional acti-
vation of PPARa-regulated genes.20,32 The Acox1-null
mice also develop a high incidence of hepatocellular car-
cinomas.32 These effects are attributed to Acox1 substrates,1404such as long-chain and very-long-chain fatty acids, fatty
acyl CoAs, and other biological molecules that remain
unmetabolized in the absence of Acox1; some of these
substrates then function as endogenous activators of
PPARa.32 Thus, Acox1 was the ﬁrst enzyme demonstrated
to be involved in the metabolism of endogenous PPARa
ligands.32 Subsequent studies with other mice with defects
in enzymes of FAO established the concept that metabolic
pathways that generate and degrade endogenous PPARa
ligands exist to modulate lipid metabolism. The sustained
overexpression of PPARa-regulated genes involved in FAO in
Acox1/ mice contributes to increased energy burning;
consequently, these mice develop lean body mass.20,32
We have previously reported that Acox1Dob/ob mice at-
tenuates obesity and hepatic steatosis, along with an in-
crease in insulin sensitivity.22 As expected, in these
Acox1Dob/ob mice, unmetabolized substrates of Acox1
function as endogenous ligands of PPARa to cause sus-
tained transcriptional activation of PPARa and enhanced
FAO.16,20,32,42 It is, thus, clear that excess energy burning
diminishes the development of obesity in ob/ob mice, with
the genetic model of obesity representing excess energy
consumption.22,35 Activation of PPARa in Acox1Dob/obajp.amjpathol.org - The American Journal of Pathology
Figure 7 Liver cell proliferation and induction of L-3-hydroxyacyl-CoA dehydrogenase (L-PBE) resulting from PPARa activation by dietary Wy-14,643 for 4
days. Bromodeoxyuridine (BrdUrd) labeling (A) and L-PBE immunohistochemical staining (B) of livers of 2-month-old wild-type (WT), PPARa/, ob/ob, and
PPARaDob/ob mice fed with chow diet or 0.125% Wy-14,643 for 4 days. Liver/body weight ratio (C) and hepatocyte proliferation (D) assessed by BrdUrd
labeling ratio by calculating BrdUrd-positive hepatocyte nuclei.
PPARa-Deﬁcient ob/ob Obese Micemice increased the expression of genes associated with
inﬂammation and endoplasmic reticulum stress systems
contributing to liver tumor development.22
Insights from the PPARaDob/ob Mice
As a corollary, to establish that the failure to induce PPARa-
regulated hepatic fatty acid oxidation and energy burning in
ob/ob mice impedes the progression of fatty liver disease and
development of liver tumors, we generated PPARaDob/ob
mice. In contrast to Acox1Dob/ob mice that consumed more
energy due to lack of leptin but also burnt excess energy in
view of the heightened PPARa-regulated fatty acid oxidation,
PPARaDob/ob mice, as expected, also consumed more energy
due to leptin deﬁciency but burnt less energy due to PPARa
deﬁciency. PPARaDob/ob mice gained more body weight
from the age of 24 weeks when compared to ob/ob mice,
although they consumed less food per gram weight than ob/ob
mice, suggesting a reduction in energy expenditure associated
with PPARa deﬁciency. The excess energy is conserved in
WAT in ob/ob and PPARaDob/ob mice and accounts for in-
crease in fat weight and adipocyte size.8e10 As the process
progresses, whitening of BAT ensues. Deletion of PPARa inThe American Journal of Pathology - ajp.amjpathol.orgob/ob mice aggravated fat accumulation in adipocytes,
resulting in hypertrophic fat cells.
Leptin encoded by ob gene regulates appetite, energy
homeostasis,41,43,44 and immune function.41e45 Its expres-
sion level in the adipocytes is correlated with the lipid content
and the corresponding individual adipocyte size.45 Disrup-
tion of ob gene results in excess food intake with reduced
energy expenditure, which accelerates fat accumulation in
adipose tissue and liver and inﬂuences whitening of
BAT.46e48 As a result, ob/ob mice become obese with
increased body weight and several fold increase in fat content
compared to WT mice, and become hyperinsulinemic and
hyperglycemic.46e48 Because PPARa modulates energy
homeostasis, its deletion contributes to the failure to activate
fatty acid oxidation systems, which results in an accelerated
accumulation of excess energy, ﬁrst in the adipose tissue and
then in the liver. Accordingly, as shown herein, deﬁciency of
PPARa aggravates obesity and hepatic steatosis in ob/ob
mice and inﬂuences insulin and glucose tolerance. In this
context, some PPARa ligands have been shown to reduce
hyperinsulinemia and hyperglycemia and increase insulin
sensitivity of mice fed with a high-fat diet.46,49 These
observations suggest that PPARa deﬁciency leads to1405
Figure 8 PPARaDob/ob mice fail to respond to
PPARa ligand Wy-14,643 induced body weight
reduction and liver tumorigenesis. A: Physical
appearance of chow-fed (1) or 0.05%Wy-14,643efed
(2) for 14 months (aged 16 months) wild-type (WT),
PPARa/, ob/ob, and PPARaDob/ob mice. B: Body
weight changes of mice treated with 0.05% Wy-
14,643 for 8 to 52 weeks. C: Liver appearance of WT,
PPARa/,ob/ob, and PPARaDob/obmice fednormal
chow (control) or treated with 0.05% Wy-14,643 for
14 months. Liver tumors are seen in Wy-14,643efed
WT and ob/ob mice. D: Incidence of liver tumors.
PPARa activation by Wy-14,643 induces liver tumors
in ob/ob mice, but absence of PPARa in ob/ob mice
attenuates liver tumorigenesis. All Acox1-null mice
and Acox1Dob/ob mice develop liver tumors because
of sustained PPARa activation by endogenous li-
gands. **P < 0.01 versus WT, yyP < 0.01 versus
PPARa/, and zzP < 0.01 versus ob/ob.
Gao et alimpaired fatty acid oxidation, which aggravates fat accu-
mulation and inﬂuences metabolic syndrome in ob/ob mice.
In this regard, adenoviral-mediated hyperleptinemia induces
PPARa transcription and activation of its target genes and
reduces hepatic triacylglycerol content.47 Because
adenoviral-mediated induction is transient, the effects of
hyperleptinemia reversed as the expression level of PPARa
decreased, and fat was regained 2 months after the level of
leptin return to normal.47,48,50,51 Moreover, PPARa expres-
sion can be programmed by neonatal leptin administration in
rat, which reverses the phenotypic effects of maternal un-
dernutrition.52,53 Leptin can induce liver-speciﬁc promoter
activity via a STAT3/Sp1 mechanism.54 These data suggest
that leptin deﬁciency in PPARa/ mice attenuates PPARa
activity, to further reduce FAO.
Interestingly, aging attenuated hepatic steatosis in both
ob/ob mice and PPARaDob/ob mice. Small cells with oval
nuclei arose in both the periphery of the portal tracts and
within the hepatic lobular part in PPARaDob/ob mouse
livers. These cells stained positively for hepatic oval cell
markers A6, CD45, CK19, and epithelial cell adhesion
molecule. Similar cells were not evident in the livers of
WT, PPARa/, and ob/ob mice. Hepatic oval cells,
regarded as stem/progenitor cells in adult livers, can be
activated under Dipin, partial hepatectomy, and chronic
liver injury conditions.55e59 After chronic injury or
impaired proliferation of hepatocytes, facultative adult
oval cells proliferate and differentiate into hepatocytes and
epithelial cells. Chemical hepatotoxic substances and
continuous metabolic stress can thus be considered as
potential oval cell activators. In the livers of PPARaDob/ob
mice, severe hepatic steatosis, because of excess fat over-
load and damaged FAO, leads to hepatocyte apoptosis,
with new hepatocyte proliferation independent of PPARa
to replace the dead cells.1406During acute fasting, metabolic substrates are switched
from carbohydrate to fatty acids, which leads to the release
of large quantities of free fatty acids from adipose tissue
into circulation, reaching the liver. In the liver, fatty acids
are metabolized to generate ketone bodies to serve as fuels
for other tissues. In WT and ob/ob mice, the intact PPARa
senses the inﬂux of fatty acids resulting from starvation to
up-regulate enzymes involved in FAO.39,40 We noted a
marked increase in Cyp4a1 and Cyp4a3 mRNA levels.
During fasting, PGC1a, Sirt1, and ﬁbroblast growth factor
21 were also induced in WT and ob/ob mice. Fasting
stimulated an increase in fatty acid mobilization, and an
increase in FAO resulted in the reduction of hepatic stea-
tosis in ob/ob mice, which have intact PPARa. Deletion of
PPARa in ob/ob mice resulted in severe hepatic steatosis
and reduction in plasma glucose level after 24 hours of
starvation. FAO enzymes were not induced because of
PPARa deﬁciency. In PPARa-deleted ob/obmice, PPARg
and Sirt1 expression was induced after starvation, but the
relevance is unclear. Furthermore, PPARa/ mice and
PPARaDob/ob mice fail to respond to Wy-14,643, a potent
synthetic PPARa activator. In the absence of PPARa, there
is no induction of fatty acid oxidation, peroxisome pro-
liferation, and liver tumorigenesis in PPARa/ mice and
PPARaDob/ob mice. Previous work has shown that fat
accumulation in the livers of ob/obmice alone will not lead
to liver tumors, but sustained activation of PPARa-
modulated energy expenditure by endogenous PPARa
ligands in ob/obmice resulted in liver tumor development.22
On the other hand, PPARa deﬁciency in ob/ob mice further
aggravates hepatic steatosis, but does not increase the liver
tumor risk, suggesting that fat accumulation in liver is not the
direct reason for hepatocellular carcinoma.
In summary, these observations further support the notion
that PPARa-regulated signaling plays an important role inajp.amjpathol.org - The American Journal of Pathology
PPARa-Deﬁcient ob/ob Obese Micethe progression of liver diseases in obese mice. PPARa
deﬁciency aggravates obesity-associated hepatic steatosis
without increasing liver cancer risk in ob/ob mice, whereas
heightened activation of PPARa in ob/ob fatty livers in-
creases the risk of liver cancer.Supplemental Data
Supplemental material for this article can be found at
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